FOURKITES
6.2.2024 07:25:29 CET | Business Wire | Press release
Leading supply chain visibility provider FourKites® today announced several enhancements to Dynamic Ocean®, its next-generation ocean visibility solution. By providing better context, clarity and control throughout every ocean shipment, these new features help FourKites users worldwide mitigate disruptions, including conflict on the Red Sea and low water levels in the Panama Canal; reduce costly fees like preventable detention and demurrage charges; and exceed customer expectations.
“Adding FourKites’ ocean visibility to our technology stack was an obvious choice, and it has paid off handsomely,” said Davide Busato, Logistic Competence Center Innovation Project Manager at Barilla. “Now we don’t need to spend time hunting for answers and instead can focus on more important tasks like acting on the FourKites data to improve customer satisfaction.”
Dynamic Ocean leverages multilayered data to provide a robust, dependable and continuous picture of the end-to-end supply chain. With FourKites latest releases, supply chain managers can make the right decisions quickly when unexpected disruptions arise.
Specifically, new enhancements to Dynamic Ocean include:
- Improved Dynamic ETAs and ETDs that deliver 95%+ accuracy for ETAs to the final destination; 90%+ accuracy for vessel arrival terminal predictions; and synchronised ETAs and ETDs for multiple shipments on the same vessel. FourKites ETAs are 27-37% more accurate than carrier ETAs, on average.
- Improved data quality and latency, enabling 85% of events to be provided within 8 hours of their occurrence, which is 35% faster than industry standards. FourKites Visibility and ETAs are based on multilayered, resilient data, giving customers a robust and continuous picture of their end-to-end supply chain.
- Earlier, more precise alerts that help customers proactively identify exceptions — as well as containers incurring detention and demurrage fees — to reduce risk, minimise costs and boost customer satisfaction.
- A seamless, end-to-end user interface that eliminates silos for international teams so they can avoid fines and fees, provide smoother handoffs with collaborators, and improve customer satisfaction.
With these updates, FourKites customers will continue to root out unnecessary costs and waste in their supply chain.
“Our goals with FourKites in 2024 are to track 90% of our shipments, reduce penalties with carriers by 5% and decrease inefficient communication with partners by 10-15%,” added Busato. “Thanks to FourKites’ ability to send automatic ETAs with delay updates, among other features, we’re well on our way to meeting these metrics.”
FourKites’ new ocean features also include an improved detention and demurrage dashboard and analytics to help customers reduce penalties tied to delays, manage carrier performance, and analyse cost and service levels by lane. Moreover, a real-time view of inbound inventory empowers companies to optimise safety stock and working capital, accelerate inventory turnover and delight customers through visibility-enhanced order processing, fulfillment, invoicing and collection.
Powering these enhancements is FourKites’ deep trove of supply chain data such as schedule data on 11,000+ ocean lanes and data and integrations for 100+ carriers and 3,000+ services. In addition, FourKites provides detailed in-port tracking and congestion data at 150+ major global ocean terminals.
“In the face of military conflict in the Red Sea, storms and supply shortages, end-to-end visibility is critical to resilient ocean supply chains. And when disruptions do occur, minutes matter,” says Priya Rajagopalan, Chief Product Officer at FourKites. “With our enhancements to ocean visibility, FourKites is giving cross-functional teams access to the real-time supply chain data and insights they need — helping them seamlessly integrate their international supply chain and keep their customers happy.”
Enhancements to FourKites Dynamic Ocean are available starting today. For more information, visit https://www.fourkites.com/platform/ocean-freight-visibility/.
About FourKites
Leading global supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 3.2 million shipments daily across road, rail, ocean, air, parcel and last mile, and reaching over 200 countries and territories, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,200 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240205928770/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release
The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
